For children born with achondroplasia — the most common form of short-limb dwarfism — the gap between clinical trial results and everyday clinical reality has long been a concern. This single-center retrospective analysis begins to close that gap, offering meaningful data on a therapy that many families encounter outside controlled trial conditions, including children who would typically be excluded from pivotal studies.
Over a mean treatment duration of 12.7 months, 25 children (ages 2.9–14.3 years) receiving daily subcutaneous vosoritide — a C-type natriuretic peptide (CNP) analogue that counteracts overactive FGFR3 signaling — showed statistically significant improvements in height z-scores (Δ +0.38 ± 0.45, p < .001) and arm span z-scores (Δ +0.32 ± 0.48, p = .007), using an AI-assisted growth assessment tool validated specifically for achondroplasia. Sitting height trended upward without reaching significance, and BMI z-scores remained stable — suggesting proportionate growth without excess weight gain. Notably, the eight children with prior limb-lengthening surgery showed no significant difference in response compared to those without surgical history.
Vosoritide received FDA approval in 2021 based on a pivotal trial demonstrating annualized height velocity gains of roughly 1.57 cm/year over placebo. This real-world cohort corroborates directional efficacy but adds clinically important nuance: surgical history, long a source of provider hesitation, did not appear to blunt the drug's growth-promoting effect. However, the study carries meaningful limitations — 25 patients at a single center, retrospective design, no control arm, and a follow-up period under 13 months. Z-score gains, while statistically significant, are modest and their long-term functional implications remain unknown. Whether vosoritide meaningfully alters adult stature or musculoskeletal outcomes requires larger, longer studies. For now, this analysis is best characterized as confirmatory and reassuring rather than paradigm-shifting.